Clinical Trials in Denver

Showing 3621-3640 of 15,604 trials

Cisplatin Disposition and Kidney Injury

NCT03817970

This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.

Nephrotoxicity

University of Colorado, Denver72 participantsStarted Nov 2019

Denver, Colorado, United States • New York, New York, United States

RECRUITINGNA< 1 mile

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

NCT06655207

Oli is a predictive, non-invasive device, intended to be placed on the participant's maternal abdomen during the intrapartum period, which can alert healthcare professionals of an impending cumulative blood loss of ≥500 ml (abnormal postpartum uterine bleeding) or cumulative blood loss of ≥1000ml (postpartum haemorrhage) at least 1 hour in advance of birth. This study is being undertaken to assess the performance of Oli measuring cumulative blood loss ≥500ml and ≥1000ml, as well as evaluate its safety profile.

Post Partum HaemorrhageMaternal Care PatternsHigh Risk Pregnancy

Baymatob Operations Pty Ltd1,000 participantsStarted Aug 2025

Denver, Colorado, United States • Baton Rouge, Louisiana, United States • New York, New York, United States +4 more locations

Cisplatin Disposition and Kidney Injury

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

Find Trials by Condition in Denver

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Prevention and Choice for Type 2

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis